FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172604937> ?p ?o ?g. }

• W2172604937 endingPage "42353" @default.
• W2172604937 startingPage "42345" @default.
• W2172604937 abstract "Acute myeloid leukemia (AML) is a heterogeneous disease. Even within the same NPM1-mutated genetic subgroup, some patients harbor additional mutations in FLT3, IDH1/2, DNMT3A or TET2. Recent studies have shown the prognostic significance of minimal residual disease (MRD) in AML but it remains to be determined which molecular markers are the most suitable for MRD monitoring. Recent advances in next-generation sequencing (NGS) have provided the opportunity to use multiple molecular markers. In this study, we used NGS technology to assess MRD in 31 AML patients enrolled in the ALFA-0701 trial and harboring NPM1 mutations associated to IDH1/2 or DNMT3A mutations. NPM1 mutation-based MRD monitoring was performed by RTqPCR. IDH1/2 and DNMT3A mutations were quantified by NGS using an Ion Torrent Proton instrument with high coverage (2 million reads per sample). The monitoringof IDH1/2 mutations showed that these mutations were reliable MRD markers that allowed the prediction of relapse in the majority of patients. Moreover, IDH1/2 mutation status predicted relapse or disease evolution in 100% of cases if we included the patient who developed myelodysplastic syndrome. In contrast, DNMT3A mutations were not correlated to the disease status, as we found that a preleukemic clone with DNMT3A mutation persisted in 40% of the patients who were in complete remission, reflecting the persistence of clonal hematopoiesis." @default.
• W2172604937 created "2016-06-24" @default.
• W2172604937 creator A5000436961 @default.
• W2172604937 creator A5017420578 @default.
• W2172604937 creator A5018416096 @default.
• W2172604937 creator A5022341207 @default.
• W2172604937 creator A5035494468 @default.
• W2172604937 creator A5041738624 @default.
• W2172604937 creator A5041818840 @default.
• W2172604937 creator A5043485385 @default.
• W2172604937 creator A5050651759 @default.
• W2172604937 creator A5052564121 @default.
• W2172604937 creator A5054745373 @default.
• W2172604937 creator A5054751100 @default.
• W2172604937 creator A5054902087 @default.
• W2172604937 creator A5058825074 @default.
• W2172604937 creator A5061523244 @default.
• W2172604937 creator A5062550034 @default.
• W2172604937 creator A5067465993 @default.
• W2172604937 creator A5070081356 @default.
• W2172604937 creator A5076973611 @default.
• W2172604937 creator A5077339582 @default.
• W2172604937 creator A5081514634 @default.
• W2172604937 date "2015-10-12" @default.
• W2172604937 modified "2023-10-11" @default.
• W2172604937 title "<i>IDH1/2</i>but not<i>DNMT3A</i>mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association" @default.
• W2172604937 cites W1255676896 @default.
• W2172604937 cites W1963777403 @default.
• W2172604937 cites W1974698532 @default.
• W2172604937 cites W1979099484 @default.
• W2172604937 cites W1987198309 @default.
• W2172604937 cites W1992826811 @default.
• W2172604937 cites W2004443250 @default.
• W2172604937 cites W2007302457 @default.
• W2172604937 cites W2028231895 @default.
• W2172604937 cites W2041050642 @default.
• W2172604937 cites W2042718885 @default.
• W2172604937 cites W2046829201 @default.
• W2172604937 cites W2047867594 @default.
• W2172604937 cites W2071370702 @default.
• W2172604937 cites W2076031927 @default.
• W2172604937 cites W2078972833 @default.
• W2172604937 cites W2093144236 @default.
• W2172604937 cites W2094851085 @default.
• W2172604937 cites W2109554035 @default.
• W2172604937 cites W2126212760 @default.
• W2172604937 cites W2126816979 @default.
• W2172604937 cites W2131072337 @default.
• W2172604937 cites W2135346203 @default.
• W2172604937 cites W2149858388 @default.
• W2172604937 cites W2153994826 @default.
• W2172604937 cites W2157305385 @default.
• W2172604937 cites W2169046713 @default.
• W2172604937 doi "https://doi.org/10.18632/oncotarget.5645" @default.
• W2172604937 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4747230" @default.
• W2172604937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26486081" @default.
• W2172604937 hasPublicationYear "2015" @default.
• W2172604937 type Work @default.
• W2172604937 sameAs 2172604937 @default.
• W2172604937 citedByCount "90" @default.
• W2172604937 countsByYear W21726049372016 @default.
• W2172604937 countsByYear W21726049372017 @default.
• W2172604937 countsByYear W21726049372018 @default.
• W2172604937 countsByYear W21726049372019 @default.
• W2172604937 countsByYear W21726049372020 @default.
• W2172604937 countsByYear W21726049372021 @default.
• W2172604937 countsByYear W21726049372022 @default.
• W2172604937 countsByYear W21726049372023 @default.
• W2172604937 crossrefType "journal-article" @default.
• W2172604937 hasAuthorship W2172604937A5000436961 @default.
• W2172604937 hasAuthorship W2172604937A5017420578 @default.
• W2172604937 hasAuthorship W2172604937A5018416096 @default.
• W2172604937 hasAuthorship W2172604937A5022341207 @default.
• W2172604937 hasAuthorship W2172604937A5035494468 @default.
• W2172604937 hasAuthorship W2172604937A5041738624 @default.
• W2172604937 hasAuthorship W2172604937A5041818840 @default.
• W2172604937 hasAuthorship W2172604937A5043485385 @default.
• W2172604937 hasAuthorship W2172604937A5050651759 @default.
• W2172604937 hasAuthorship W2172604937A5052564121 @default.
• W2172604937 hasAuthorship W2172604937A5054745373 @default.
• W2172604937 hasAuthorship W2172604937A5054751100 @default.
• W2172604937 hasAuthorship W2172604937A5054902087 @default.
• W2172604937 hasAuthorship W2172604937A5058825074 @default.
• W2172604937 hasAuthorship W2172604937A5061523244 @default.
• W2172604937 hasAuthorship W2172604937A5062550034 @default.
• W2172604937 hasAuthorship W2172604937A5067465993 @default.
• W2172604937 hasAuthorship W2172604937A5070081356 @default.
• W2172604937 hasAuthorship W2172604937A5076973611 @default.
• W2172604937 hasAuthorship W2172604937A5077339582 @default.
• W2172604937 hasAuthorship W2172604937A5081514634 @default.
• W2172604937 hasBestOaLocation W21726049371 @default.
• W2172604937 hasConcept C104317684 @default.
• W2172604937 hasConcept C126322002 @default.
• W2172604937 hasConcept C127848430 @default.
• W2172604937 hasConcept C143998085 @default.
• W2172604937 hasConcept C2483381 @default.
• W2172604937 hasConcept C2778461978 @default.
• W2172604937 hasConcept C2778729363 @default.

• next